(Photo Courtesy: www.ineradicablestain.com)
Vyome is involved in the development of next generation antibiotics and antifungal agents that target antimicrobial resistance for opportunist pathogens of the skin.
The results, in the form of three important studies, describing its DART (Dual Action Rational Therapeutics) antibiotics and clinical results from its antifungal Molecular Replacement Therapy (MRT) technology platform, were presented at the American Society of Microbiology Interscience Conference of Antimicrobial Agents and Chemotherapy (ASM - ICAAC) in San Diego, California, USA.
In the first study, Vyome scientists characterized the skin microbiome of acne patients where the study showed the presence of antibiotic-resistant bacteria Propionibacterium acne and Staphylococcus epidermidis in the acne lesions.
The study identified the mutations that lead to resistance against the currently used antibiotics, and highlights the need to personalize acne treatment by selecting the right antibiotic to kill the bacteria.
Vyome has its lead program VB1953, a novel drug targeting antibiotics resistant acne market of USD 3 Bn, for which IND (Investigational New Drug) application will be filed with the USFDA in Q4 2015.